All the events here are relevant to people working in dementia research. If you would like to add your own you can:
2026: Biomarker Strategies for FTD Clinical Trials
September 22 - September 24
AFTD is dedicated to improving the lives of families coping with FTD and to advancing research into effective treatments and a cure. The FTD Research Roundtable provides a precompetitive space for biopharmaceutical companies to partner and advance drug development for FTD, with input from regulators and scientific leaders, all of whom share a common interest in eliminating barriers to success in FTD clinical trials. If you are working on FTD drug development or a related field and you think that you should participate in the Roundtable, please get in touch with research@theaftd.org.
There has been immense growth in companies focusing on FTD drug development. However, all companies face similar challenges in FTD drug development. AFTD and scientific leaders are seeking to provide a space in which industry can have precompetitive discussions on FTD clinical trial barriers, seeking solutions, proposing best practices and ultimately enable FTD drug development in the past several years. As a result, the FTD Research Roundtable was developed.
Each program is selected and designed based upon the priorities of the Steering Committee, with insight from regulators, scientific leaders, and advocates.
2026: Biomarker Strategies for FTD Clinical Trials
Date: September 22-24, 2026
Agenda: Coming soon
Leadership Committee:
- Howard “Howie” Rosen, MD, Academic Co-Chair
- Gary Romano, MD, PhD, Industry Co-Chair
- Carmela Tartaglia, MD, FRCPC, Academic Chair-Elect
- Richard Tsai, MD, MBA, Industry Chair-Elect
- Michelle Campbell, PhD, US Food & Drug Administration, Division of Neuroscience
- Steffen Thirstrup, MD, PhD, European Medicines Agency
- Glenn Harris, PhD, Rainwater Charitable Foundation
- Penny Dacks, PhD, AFTD
- Julia Pierrat, FTD Family Advocate
Steering Committee Members
- Acelot
- AFTD
- Alexion
- AviadoBio
- Bluefield Project to Cure FTD
- Coya Therapeutics
- Critical Path Institute
- Denali Therapeutics
- European Medicines Agency
- Orchard Therapeutics
- Otsuka
- Passage Bio
- Rainwater Charitable Foundation
- US Food & Drug Administration
- VectorY Therapeutics
